Register entry
ONYX PHARMACEUTICALS INC A WHOLLY OWNED SUB OF AMGEN INC
- Registered sites
- 0
- Drug products
- 0
- Live patents
- 27
- Countries
- 0
- Base
- Unknown
Sites
Facilities
0No registered facilities
This company holds drug listings or approvals but operates no registered establishment of its own, which is normal for an NDA holder that outsources manufacturing.
Exclusivity
Patents
27Unexpired Orange Book patents where this company is the application holder.
| Product | Active ingredient | Expiry |
|---|---|---|
| KYPROLIS | CARFILZOMIB | Jan 2027 |
| KYPROLIS | CARFILZOMIB | Dec 2027 |
| KYPROLIS | CARFILZOMIB | Jun 2028 |
| KYPROLIS | CARFILZOMIB | Oct 2029 |
| KYPROLIS | CARFILZOMIB | Apr 2030 |
| KYPROLIS | CARFILZOMIB | Feb 2033 |
| KYPROLIS | CARFILZOMIB | Aug 2033 |
| KYPROLIS | CARFILZOMIB | Apr 2041 |
| KYPROLIS | CARFILZOMIB | Oct 2041 |
Provenance
Facility and operations data from the FDA Drug Establishments Current Registration Site. Product data from the openFDA National Drug Code Directory. Patent and exclusivity data from the FDA Orange Book. Shortage data from the FDA drug shortage database. Contact details the FDA publishes for registered establishments are deliberately not reproduced here. This entry is compiled from public records and has not been claimed by the company.